Involvement of Interferon Regulatory Factor 7 in Nicotine's Suppression of Antiviral Immune Responses.
Antiviral immune response
CRISPR/Cas9
Interferon regulatory factor 7
Nicotine
Poly I:C
Journal
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
ISSN: 1557-1904
Titre abrégé: J Neuroimmune Pharmacol
Pays: United States
ID NLM: 101256586
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
10
11
2018
accepted:
05
03
2019
pubmed:
4
6
2019
medline:
6
10
2020
entrez:
3
6
2019
Statut:
ppublish
Résumé
Nicotine, the active ingredient in tobacco smoke, suppresses antiviral responses. Interferon regulatory factors (IRFs) regulate transcription of type I interferons (IFNs) and IFN-stimulated genes (ISGs) in this response. IRF7 is a key member of the IRF family. Expression of Irf7 is elevated in the brains of virus-infected animals, including human immunodeficiency virus-1 transgenic (HIV-1Tg) rats. We hypothesized that IRF7 affects nicotine's modulation of antiviral responses. Using CRISPR/Cas9 system, IRF7-mutant cell lines were created from human embryonic kidney 293FT cells in which 16 nicotinic acetylcholine receptors (nAChRs) were detected. Decreased expression of IRF7 was confirmed at both the mRNA and protein levels, as was IRF7-regulated cell growth in two IRF7-mutant cell lines, designated IRF7-Δ7 and IRF7-Δ11. In IRF7-Δ7 cells, expression of two nAChR genes, CHRNA3 and CHRNA9, changed modestly. After stimulation with polyinosinic-polycytidylic acid (poly I:C) (0.25 μg/ml) for 4 h to mimic viral infection, 293FT wild-type (WT) and IRF7-Δ7 cells were treated with 0, 1, or 100 μM nicotine for 24 h, which increased IFN-β expression in both types of cells but elevation was higher in WT cells (p < 0.001). Expression was significantly suppressed in WT cells (p < 0.001) but not in IRF7-Δ7 cells by 24-h nicotine exposure. Poly I:C stimulation increased mRNA expression of retinoic-acid-inducible protein I (RIG-I), melanoma-differentiation-associated gene 5 (MDA5), IFN-stimulated gene factor 3 (ISG3) complex, and IFN-stimulated genes (IRF7, ISG15, IFIT1, OAS1); nicotine attenuated mRNA expression only in WT cells. Overall, IRF7 is critical to nicotine's effect on the antiviral immune response. Graphical Abstract Involvement of IRF7 in nicotine's suppression of poly I:C-induced antiviral immune responses. PAMPs, such as a synthetic viral analogue of dsRNA poly I:C attack cells, will be recognized by PRRs, and the host innate immunity against viral infection will be activated. PRRs signaling trigger phosphorylation of IRF7 and IRF3 to induce their translocation to the nucleus and result in the production of type I IFNs. Then IFNs bind to IFNAR to activate the transcription factor ISGF3, a complex consisting of STAT1, STAT2, and IRF9. Further, it induces the expression of ISGs, including IFIT1, OAS1, IRF7, ISG15, etc. Nicotine suppresses the immune responses stimulated by poly I:C. In the IRF7-mutant cells, nicotine's suppressive effects on poly I:C-stimulated immune responses were restrained.
Identifiants
pubmed: 31154625
doi: 10.1007/s11481-019-09845-2
pii: 10.1007/s11481-019-09845-2
doi:
Substances chimiques
Antiviral Agents
0
IRF7 protein, human
0
Interferon Regulatory Factor-7
0
Nicotine
6M3C89ZY6R
Poly I-C
O84C90HH2L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-564Références
Neuroscience. 2002;113(3):493-507
pubmed: 12150770
J Cancer. 2017 Jan 13;8(2):207-219
pubmed: 28243325
Acta Neurobiol Exp (Wars). 2013;73(1):1-18
pubmed: 23595280
Sci Rep. 2015 Oct 28;5:15895
pubmed: 26507386
FEBS Lett. 1998 Dec 11;441(1):106-10
pubmed: 9877175
Psychopharmacology (Berl). 2006 Nov;189(1):125-33
pubmed: 16977477
Science. 1994 Jun 3;264(5164):1415-21
pubmed: 8197455
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5746-51
pubmed: 10318955
J Pharmacol Toxicol Methods. 2005 May-Jun;51(3):187-200
pubmed: 15862464
N Engl J Med. 2015 Feb 12;372(7):631-40
pubmed: 25671255
Nat Rev Immunol. 2006 Sep;6(9):644-58
pubmed: 16932750
Nat Rev Immunol. 2008 Jul;8(7):559-68
pubmed: 18575461
J Biol Chem. 2010 Dec 31;285(53):42013-22
pubmed: 20943654
J Interferon Cytokine Res. 2002 Jan;22(1):49-58
pubmed: 11846975
BMC Genomics. 2016 Jan 25;17:76
pubmed: 26810609
Mol Immunol. 2009 Feb;46(5):821-9
pubmed: 18930547
Psychopharmacology (Berl). 1999 Feb;142(2):193-9
pubmed: 10102772
J Natl Cancer Inst. 2010 Sep 8;102(17):1322-35
pubmed: 20733118
Nat Rev Immunol. 2001 Nov;1(2):135-45
pubmed: 11905821
Neuropharmacology. 2014 Apr;79:715-25
pubmed: 24467848
Genes Dev. 1993 May;7(5):812-21
pubmed: 8491378
Mult Scler. 2013 Jul;19(8):1009-13
pubmed: 23319071
Annu Rev Neurosci. 2002;25:563-93
pubmed: 12052921
PLoS One. 2016 Nov 15;11(11):e0166565
pubmed: 27846263
Prog Brain Res. 2000;126:255-62
pubmed: 11105651
Nat Rev Immunol. 2009 Aug;9(8):535-42
pubmed: 19556980
PLoS One. 2015 Apr 23;10(4):e0125116
pubmed: 25906356
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Nature. 2001 Oct 18;413(6857):732-8
pubmed: 11607032
Cold Spring Harb Symp Quant Biol. 2013;78:105-16
pubmed: 24092468
Oncogene. 2017 May 25;36(21):2969-2980
pubmed: 28092673
Genes Immun. 2011 Sep;12(6):399-414
pubmed: 21490621
Am J Physiol Lung Cell Mol Physiol. 2014 Dec 1;307(11):L848-58
pubmed: 25260755
Gene. 2015 Sep 15;569(2):182-90
pubmed: 26026906
Nat Rev Microbiol. 2018 Jul;16(7):423-439
pubmed: 29769653
J Interferon Cytokine Res. 2008 Mar;28(3):167-79
pubmed: 18338949
Virus Res. 2015 Jan 2;195:112-8
pubmed: 25300801
Science. 2015 Apr 24;348(6233):448-53
pubmed: 25814066
Exp Cell Res. 1986 Sep;166(1):209-19
pubmed: 2874992
Arch Intern Med. 2004 Nov 8;164(20):2206-16
pubmed: 15534156
Immunity. 2006 Sep;25(3):349-60
pubmed: 16979567
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Mov Disord. 2012 Jul;27(8):947-57
pubmed: 22693036
Immunity. 2000 Oct;13(4):539-48
pubmed: 11070172
Cell. 1993 Aug 27;74(4):609-19
pubmed: 8358790
J Innate Immun. 2017;9(2):145-161
pubmed: 27811478
Nat Immunol. 2004 Jul;5(7):730-7
pubmed: 15208624
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
Nat Rev Immunol. 2002 May;2(5):372-7
pubmed: 12033743
J Interferon Cytokine Res. 2011 Jan;31(1):71-8
pubmed: 20950130
Annu Rev Immunol. 2001;19:623-55
pubmed: 11244049
PLoS Pathog. 2009 Oct;5(10):e1000607
pubmed: 19798431
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3501-6
pubmed: 11248107
PLoS One. 2013;8(3):e59582
pubmed: 23536882
Front Biosci. 2008 Jan 01;13:492-504
pubmed: 17981563
Am J Respir Cell Mol Biol. 2011 Jan;44(1):118-26
pubmed: 20224072
Nat Commun. 2017 Mar 14;8:14716
pubmed: 28291770
Nature. 2005 Apr 7;434(7034):772-7
pubmed: 15800576
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
Nature. 2006 May 4;441(7089):101-5
pubmed: 16625202
Anticancer Res. 2017 Aug;37(8):4415-4424
pubmed: 28739735
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
EMBO J. 1995 Feb 1;14(3):603-9
pubmed: 7859748
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13500-7
pubmed: 8942963
Cell. 2014 Jun 5;157(6):1262-78
pubmed: 24906146
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Nat Rev Immunol. 2009 May;9(5):377-84
pubmed: 19330016
Cell Res. 2006 Feb;16(2):141-7
pubmed: 16474426
Oncol Res. 2017 Apr 14;25(4):511-522
pubmed: 27733217
J Neuroimmune Pharmacol. 2016 Sep;11(3):562-71
pubmed: 27147085
Postgrad Med J. 2009 Apr;85(1002):196-201
pubmed: 19417169
Cell Physiol Biochem. 2014;33(2):389-401
pubmed: 24525957